m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00745)
Name
GW841819X
Synonyms
KB-75882
    Click to Show/Hide
Status
Investigative
Structure
Formula
C25H21N5O2
InChI
1S/C25H21N5O2/c1-17-28-29-24-23(27-25(31)32-16-18-10-4-2-5-11-18)26-22(19-12-6-3-7-13-19)20-14-8-9-15-21(20)30(17)24/h2-15,23H,16H2,1H3,(H,27,31)
InChIKey
TUWDLUFFAHHNEF-UHFFFAOYSA-N
PubChem CID
13953710
TTD Drug ID
D03LIP
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Bromodomain-containing protein 4 (BRD4)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Bromodomain-containing protein 4 (BRD4) is a therapeutic target for GW841819X. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GW841819X through regulating the expression of Bromodomain-containing protein 4 (BRD4). [1], [2]
References
Ref 1 mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. 2018 Sep;561(7724):556-560. doi: 10.1038/s41586-018-0538-8. Epub 2018 Sep 19.
Ref 2 Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33. doi: 10.1038/nature10509.